Form 4: Rocket Pharmaceuticals Executes Option Exchange Program

Rocket Pharmaceuticals officer John Militello participated in an option exchange program, cancelling underwater options for new grants at $3.00 per share.

Summary

• Reporting person John Militello, VP of Finance and Principal Accounting Officer, participated in a company-wide option exchange program on May 26, 2026.
• A total of 278,766 previously granted 'out-of-the-money' stock options with exercise prices ranging from $10.85 to $62.32 were cancelled.
• In exchange, the reporting person received 116,562 replacement stock options with a new exercise price of $3.00 per share.
• The new options have varying vesting schedules, with significant portions vesting on May 26, 2027, and May 26, 2028.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event; while it indicates past stock underperformance, it is a standard retention mechanism for executive teams in the biotech industry.

Positives

• The exchange program aligns management incentives with the current market price of the company's stock.
• The program serves as a retention tool for key personnel by providing meaningful equity incentives despite previous share price declines.

Negatives

• The necessity of an option exchange program indicates that a significant number of previous equity grants were deeply underwater, reflecting poor historical stock performance.
• The exchange results in a reduction of the total number of options held by the reporting person (from 278,766 to 116,562).

Risks

• Continued share price volatility could render the new $3.00 options underwater again.
• Reliance on equity-based compensation may be impacted if the company fails to meet clinical or commercial milestones.

Future Outlook

The company is utilizing this exchange to maintain executive retention and incentive alignment, contingent upon continued employment.

Management Comments

• The exchange was conducted pursuant to an option exchange program for eligible out-of-the-money stock options.

Industry Context

StockSavvy.ai notes that option exchange programs are common in the biotechnology sector during periods of prolonged market downturns to prevent the loss of key talent when historical equity grants lose their retention value.

Comparison to Industry Standards

• Option repricing or exchange programs are a standard corporate governance tool in high-growth, high-volatility sectors like biotech.
• The $3.00 strike price reflects the market valuation at the time of the exchange, consistent with Nasdaq compliance requirements.

Corporate Governance

Stakeholder Impact

• Shareholders may view the repricing as a dilution of the original incentive structure, though it is intended to retain leadership.

Next Steps

• Continued employment of the reporting person to satisfy vesting requirements for the new options.

Key Dates

Keywords

Rocket Pharmaceuticals, RCKT, Option Exchange, Executive Compensation, Insider Trading, Biotech